Palatin Technologies, Inc.

Palatin Technologies Inc (Palatin) is a biopharmaceutical company that undertakes the development of targeted, receptor-specific peptide therapeutics. The company’s development programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its clinical pipeline includes melanocortin receptor programs such as Bremelanotide MC4r Agonist for hypoactive sexual desire disorder, PL-8177 MC1r Agonist for inflammatory bowel disease and PL-8331 MC1/5r Agonist for anti-inflammatory ocular indications; and natriuretic peptide receptor programs including PL-3994 NPR-A for heart failure and PL-5028 NPR-A/C Agonist for heart failure and fibrosis. Palatin is headquartered in Cranbury, New Jersey, the US.The company reported revenues of (US Dollars) US$67.1 million for the fiscal year ended June 2018 (FY2018), an increase of 50.1% over FY2017. The operating profit of the company was US$25.9 million in FY2018, compared to an operating loss of US$10.6 million in FY2017. The net profit of the company was US$24.7 million in FY2018, compared to a net loss of US$13.3 million in FY2017. Company United States 4B Cedar Brook Dr jwinters@palatin.com http://www.palatin.com